Synvisc One is an innovative injectable product to address joint pain associated with osteoarthritis. By having a strong effect on synovial tissue, it turns out to be effective even when it comes to patients with severely inflamed knee joints. The composition of Synvisc One is based on the following ingredients:
– Hylan-polymers (or, more precisely, hylan G-F 20). These are the substances that might be found in chicken combs. They function as the main active ingredients of the product;
– Sodium chlorides. These are the auxilary substances used to strengthen the efficiency of hylan-polymers and, therefore, ensure the best possible result after the injection of the product.
It is also worth mentioning that the composition of Synvisc One does not contain prefilled lidocaine hydrochloride. Still, a healthcare professional might apply a topical anesthetic to the planned injection site to minimize the discomfort og a patient during the procedure.
The manufacturer of Synvisc One is Sanofi. It is a global pharmaceutical company with headquarters in France. Apart from Synvisc, Sanofi also produces Adlyxin, Allegra, Apidra, and other medical solutions intended for professional use.
Synvisc One is a minimally invasive injectable product intended for professional use. Only a certified healthcare provider is eligible to administer it into a patient’s joint or buy it online. While the standard package of Synvisc One includes one prefilled syringe with 6 ml of the product per unit.
Usage Indications
The main purpose of Synvisc One is to minimize the joint pain in the knee that occurs due to osteoarthritis. More precisely, it belongs to the class of minimally invasive pain-relieving intra-articular injectable products used to lubricate and cushion the joints affected by the disease.
Only a patient with osteoarthritis who failed to respond adequately to other non-invasive methods to address joint pain (such as conservative nonpharmacologic therapy or intake of simple analgesics) is usually prescribed with Synvisc One.
These days, Synvisc One is one of the most popular minimally-invasive injectable products used to treat joint pain in patients living with osteoarthritis. A significant number of individuals all around the world use it to effectively relieve their unpleasant feelings and return to their usual level of mobility.
Contraindications
Although being characterized by exceptional safety and causing no complications under normal circumstances, Synvisc One should not be administered into the joint of a patient if a patient has any of the following contraindications to the treatment:
– An allergic reaction to any component of the product (especially hylan G-F-20);
– A serious health issue (for instance, untreated epilepsy, autoimmune disease, or diabetes mellitus);
– An ongoing skin irritation around the injection site;
– An intake of any incompatible with Synvisc One medications that might lead to unwanted drug interactions.
It is also worth mentioning that all hyaluronan-based products (including Synvisc One) should not be used to treat patients with known hypersensitivity to eggs, birds, and feathers. Moreover, they are not recommended for women during pregnancy or breastfeeding and patients under the age of 21.
Possible Side Effects
As clinical trials show, Synvisc One does not usually lead to any adverse reactions. Still, some patients might experience certain side effects after the procedure. The most common ones among them are the fluid build-up at the area of the treatment, joint irritation (including effusion, stiffness, swelling, or warmth), and temporary injection site pain or discomfort in the target knee.
In the majority of cases, side effects that are mentioned above do not require any special treatment. They usually fade away on their own in two to five days after the injection process without any medical supervision.
Expected Results and After-Care Recovery Recommendations
Under normal circumstances, the expected results of Synvisc One last up to 6 months. Their exact duration, however, strongly depends on the individual peculiarities of each patient, including their current age and health condition.
To maximize the efficiency of the treatment, a patient would need to undergo follow-up injections of Synvisc One from time to time. While the adherence to these after-treatment recovery recommendations for the first several days after the procedure can minimize the risk of any complications:
– Avoidance of prolonged weight-bearing activities and strenuous exercising;
– Evasion of the usage of any products that contain quaternary ammonium salts at the injection site;
– Restraint from spending too much time on feet.
If a patient experiences inflammation or pain around the injection site after the procedure, a pack of ice might be applied to the area of the treatment for a short period of time. This way, an enhanced level of comfort might be achieved after the injection.
